Cancerkin’s News Update…
A walk in the park…
On Sunday 17 June, hundreds of Cancerkin supporters walked 10k around Hyde Park in support of those with breast cancer and to celebrate our 25th Anniversary. It was a special day of smiles, laughter and glorious sunshine – we could not have asked for better weather. Visit our website to see for yourself how much fun was had and to spot your photo. We would like to thank all our walkers (pets included!), our special guest Tom Conti, our sponsors – GAM, Sainsburys and Ocean Spray – and our fantastic team of volunteers who made the day such a success.
We have been overwhelmed with positive feedback about the walk and are so pleased to hear so many people enjoyed themselves. If you have any comments you would like to share, then please do get in contact with Laura on firstname.lastname@example.org.
If you successfully completed the walk, you will now be busy collecting up your sponsorship money. To be in with a chance of winning luxury products generously donated by our sponsor perfumery Floris, your sponsorship money must be at the Cancerkin Centre by Friday 17th August. On this day, we will count up how much has been raised in total and we will announce our top three fundraisers. Please ensure that (1) you do not send cash in the post, (2) cheques are made payable to Cancerkin and (3) your envelope is clearly marked for the Hyde Park Walk. If you have any questions, contact Laura on the email address above.
Cancerkin at Hampstead Theatre on 10 October 2012
We are thrilled to be hosting a charity performance of The Judas Kiss staring Rupert Everett at the Hampstead Theatre on Wednesday 10 October 2012 in honour of Breast Cancer Awareness Month and to celebrate Cancerkin’s 25th Anniversary.
The Judas Kiss depicts the life of Oscar Wilde, who will be played by renowned actor Rupert Everett. It describes two pivotal moments in Wilde’s life that lead him on a path to destruction: the day Wilde decides to stay in England and face imprisonment, and the night, after his release two years later, when the lover for whom he risked everything betrays him. With a quiet but burning sense of outrage, author David Hare presents the consequences of taking an uncompromisingly moral position in a world defined by fear, expedience and conformity. Directed by Neil Armfield and featuring a sparkling cast, the production is not to be missed.
Tickets will go on sale at the beginning of July. You will receive your invitation and reservation form in the post over the next few weeks or you can contact Laura on email@example.com to make a booking. Given the speed at which seats sold out last year for the performance of ‘The Last of the Duchess,’ we advise that you reserve early to avoid disappointment and to receive a special discount.
We will need volunteers over the next few weeks to help fold letters and stuff envelopes for our upcoming event. If you would like to help out, we would love to hear from you. Tea and biscuits will of course be provided. Please contact Laura or Alice on firstname.lastname@example.org.
In the news…
More support for women with breast cancer recurrence
The results of the first UK study into the number of breast cancer patients who develop the disease for a second time has prompted calls for the NHS to do more to help women with a recurrence. The study, conducted by researchers at St James’s Institute of Oncology in Leeds, has found that over one in five breast cancer patients will see their cancer return within ten years.
Researchers looked at 1,000 consecutive patients diagnosed with breast cancer in Leeds between January 1999 and March 2002. They monitored their health over a period of ten years after their first diagnosis. Excluding 54 patients who could not be followed up, 214 patients, or 22.6 percent, developed recurrent disease. Preliminary results show that, of these patients, 51 percent lived for over three years disease-free before their recurrence and on average survived for at least one year after their recurrence, with five percent living for at least ten years after.
Jane Maher, Macmillan’s chief medical officer, said of the results: “Far too many [patients with recurrent breast cancer] are given little practical or emotional support, the assumption being that they know what to expect from the first time they were treated. The NHS is focusing a lot of attention on people who don’t have problems and not enough on people who do. Women who have recurrent disease don’t get the same support and care as people who have had a primary diagnosis of breast cancer.”
In response to the study, Cancer Research UK warned that Macmillan’s figures were ‘crude’. Prof Peter Johnson, of Cancer Research UK, said: “The chance of cancer coming back for any particular woman is influenced by several factors such as whether they have passed the menopause, the size and grade of the tumour, whether it has spread to lymph nodes and whether it has hormone receptors, so crude figures for large numbers are not helpful to individual women. In fact, for many women the chance of cancer coming back is much lower than one in five.”
Dr Rachel Greig, Senior Policy Officer at Breakthrough Breast Cancer says: “We welcome this study as a useful first step towards knowing how many breast cancer patients might experience a recurrence of their disease. It is vital to know how many patients’ breast cancer are likely to return to allow the NHS to better plan and provide for their needs. We may need further studies from different parts of the country before we can accurately say what the true rate of breast cancer recurrence is nationally.”